How to achieve a predictable basal insulin? (Q36359175)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16389895%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

How to achieve a predictable basal insulin? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16389895%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

P Kurtzhals

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16389895%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 September 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16389895%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

published in

Diabetes and Metabolism

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16389895%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16389895%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

4 Pt 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16389895%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

4S25-4S33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16389895%20AND%20SRC:MED&resulttype=core&format=json

Basal and 24-h C-peptide and insulin secretion rate in normal man

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Novel forms of insulin delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Subcutaneous Insulin Absorption Explained by Insulin's Physicochemical Properties: Evidence From Absorption Studies of Soluble Human Insulin and Insulin Analogues in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Monomeric insulins obtained by protein engineering and their medical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Monomeric insulins and their experimental and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Insulin analogs with improved pharmacokinetic profiles

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Physiological insulin replacement in type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Absorption of isophane (NPH) insulin and its clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Variability of insulin absorption and insulin action

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Limitations to subcutaneous insulin administration in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Insulins today and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Insulin analogues and other developments in insulin therapy for diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Hypoglycaemia in the diabetic child

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

New insulins in the treatment of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Soluble, prolonged-acting insulin derivatives. I. Degree of protraction and crystallizability of insulins substituted in the termini of the B-chain

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Soluble, prolonged-acting insulin derivatives. II. Degree of protraction and crystallizability of insulins substituted in positions A17, B8, B13, B27 and B30

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

The cobalt(III)-insulin hexamer is a prolonged-acting insulin prodrug

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Crystal structure of a prolonged-acting insulin with albumin-binding properties

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Mechanism of protracted metabolic effects of fatty acid acylated insulin, NN304, in dogs: retention of NN304 by albumin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Mode of transcapillary transport of insulin and insulin analog NN304 in dog hindlimb: evidence for passive diffusion

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Albumin binding of acylated insulin (NN304) does not deter action to stimulate glucose uptake

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1262-3636%2805%2988264-3

7 January 2021

10.1016/S1262-3636(05)88264-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16389895%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference